NFE2L2 and neoplasm: In an oncogenic context, the aberrant activation of NRF2 leads to elevated oxidative stress tolerance, enhanced proliferation, tumor progression, and altered metabolic reprogramming, that collectively contribute to resistance against chemotherapy and radiotherapy [7].